Fulgent Genetics (FLGT) Stock Forecast, Price & News

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Fulgent Genetics in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" FLGT shares.
View FLGT analyst ratings or view top-rated stocks.

3 brokers have issued 1 year price targets for Fulgent Genetics' stock. Their FLGT share price forecasts range from $37.00 to $45.00. On average, they expect the company's stock price to reach $42.33 in the next year. This suggests a possible upside of 53.0% from the stock's current price.
View analysts price targets for FLGT or view top-rated stocks among Wall Street analysts.

Fulgent Genetics' stock was trading at $29.78 at the start of the year. Since then, FLGT shares have decreased by 7.1% and is now trading at $27.67.
View the best growth stocks for 2023 here.

Fulgent Genetics saw a increase in short interest in the month of August. As of August 31st, there was short interest totaling 597,900 shares, an increase of 9.2% from the August 15th total of 547,400 shares. Based on an average daily trading volume, of 210,500 shares, the days-to-cover ratio is currently 2.8 days. Approximately 3.2% of the shares of the company are short sold.
View Fulgent Genetics' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Monday, November 6th 2023.
View our FLGT earnings forecast.

Fulgent Genetics, Inc. (NASDAQ:FLGT) posted its quarterly earnings data on Friday, August, 4th. The company reported ($0.33) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.59) by $0.26. The company earned $67.85 million during the quarter, compared to analyst estimates of $62.68 million. Fulgent Genetics had a negative trailing twelve-month return on equity of 3.29% and a negative net margin of 15.84%.

ETFs with the largest weight of Fulgent Genetics (NASDAQ:FLGT) stock in their portfolio include ETFMG Treatments Testing and Advancements ETF (GERM), ROBO Global Healthcare Technology and Innovation ETF (HTEC), SPDR S&P Health Care Services ETF (XHS), Global X Genomics & Biotechnology ETF (GNOM) and Invesco S&P SmallCap Health Care ETF (PSCH).First Trust Nasdaq Lux Digital Health Solutions ETF (EKG).

Fulgent Genetics updated its FY 2023 earnings guidance on Friday, August, 4th. The company provided EPS guidance of -$0.95--$0.95 for the period, compared to the consensus estimate of -$0.34. The company issued revenue guidance of -.

Based on aggregate information from My MarketBeat watchlists, some companies that other Fulgent Genetics investors own include NVIDIA (NVDA), CRISPR Therapeutics (CRSP), Inseego (INSG), NeoGenomics (NEO), Invitae (NVTA), Block (SQ), JD.com (JD), Marvell Technology (MRVL), Teladoc Health (TDOC) and Editas Medicine (EDIT).

(FLGT) raised $60 million in an initial public offering on Thursday, September 29th 2016. The company issued 4,600,000 shares at $12.00-$14.00 per share. Credit Suisse and Piper Jaffray served as the underwriters for the IPO and Raymond James and BTIG were co-managers.

Fulgent Genetics trades on the NASDAQ under the ticker symbol "FLGT."

Fulgent Genetics' stock is owned by a number of institutional and retail investors. Top institutional investors include BlackRock Inc. (12.13%), Dimensional Fund Advisors LP (3.50%), State Street Corp (2.53%), Nuveen Asset Management LLC (1.38%), Nuveen Asset Management LLC (1.38%) and Geode Capital Management LLC (1.38%). Insiders that own company stock include Hanlin Gao, Jian Xie, John C Bolger, Paul Kim and X Cycle LP Tcv.
View institutional ownership trends.

Shares of FLGT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of FLGT stock can currently be purchased for approximately $27.67.

Fulgent Genetics (NASDAQ:FLGT) has a market capitalization of $828.16 million and generates $618.97 million in revenue each year. The company earns $143.40 million in net income (profit) each year or ($1.64) on an earnings per share basis.

The company employs 1,012 workers across the globe.

Fulgent Genetics' mailing address is 4978 SANTA ANITA AVENUE, TEMPLE CITY CA, 91780. The official website for the company is www.fulgentgenetics.com. The company can be reached via phone at (626) 350-0537, via email at nborsje@blueshirtgroup.com, or via fax at 626-454-1667.